| Systemic Lupus Erythematosus Research | Lifetime | 235 | GR 4 | 99.20 |
| Ocular Diseases and Behçet’s Syndrome | Lifetime | 91 | GR 1 | 98.97 |
| Systemic Sclerosis and Related Diseases | Lifetime | 123 | GR 2 | 98.82 |
| Retinal and Optic Conditions | Lifetime | 134 | GR 1 | 99.01 |
| Rheumatoid Arthritis Research and Therapies | Lifetime | 304 | GR 1 | 98.74 |
| Autoimmune and Inflammatory Disorders Research | Lifetime | 280 | GR 1 | 98.14 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | Lifetime | 487 | GR 3 | 97.56 |
| Cardiovascular Health and Disease Prevention | Lifetime | 701 | GR 20 | 97.01 |
| Inflammatory Myopathies and Dermatomyositis | Lifetime | 218 | GR 2 | 96.98 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 575 | GR 7 | 96.51 |
| Inflammasome and immune disorders | Lifetime | 524 | GR 3 | 95.47 |
| Vasculitis and related conditions | Lifetime | 467 | GR 3 | 95.98 |
| Spondyloarthritis Studies and Treatments | Lifetime | 392 | GR 2 | 96.26 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 857 | GR 9 | 94.06 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 643 | GR 6 | 92.52 |
| Otitis Media and Relapsing Polychondritis | Lifetime | 305 | GR 1 | 92.16 |
| Dermatological and COVID-19 studies | Lifetime | 714 | GR 7 | 77.27 |
| Systemic Lupus Erythematosus Research | 2021-2025 | 28 | GR 3 | 99.14 |
| Systemic Sclerosis and Related Diseases | 2021-2025 | 27 | GR 1 | 98.53 |
| Autoimmune and Inflammatory Disorders Research | 2021-2025 | 59 | GR 1 | 98.33 |
| Rheumatoid Arthritis Research and Therapies | 2021-2025 | 79 | GR 2 | 98.43 |
| Inflammasome and immune disorders | 2021-2025 | 209 | GR 2 | 92.63 |
| Spondyloarthritis Studies and Treatments | 2021-2025 | 140 | GR 2 | 95.74 |
| Inflammatory Myopathies and Dermatomyositis | 2021-2025 | 120 | GR 1 | 93.95 |
| Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis | 2021-2025 | 471 | GR 4 | 92.46 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 318 | GR 5 | 92.95 |
| Ocular Diseases and Behçet’s Syndrome | 2021-2025 | 256 | GR 1 | 90.93 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 319 | GR 12 | 87.71 |
| Eosinophilic Disorders and Syndromes | 2021-2025 | 394 | GR 1 | 85.89 |
| Cardiovascular Health and Disease Prevention | 2021-2025 | 685 | GR 23 | 85.01 |
| Cardiovascular Health and Risk Factors | 2021-2025 | 587 | GR 3 | 82.45 |
| Dermatologic Treatments and Research | 2021-2025 | 566 | GR 2 | 81.92 |
| Dermatological and COVID-19 studies | 2021-2025 | 161 | GR 4 | 77.84 |
| Adrenal Hormones and Disorders | 2021-2025 | 828 | GR 15 | 66.17 |
| Mast cells and histamine | 2021-2025 | 795 | GR 7 | 64.88 |
| Sodium Intake and Health | 2021-2025 | 862 | GR 22 | 59.81 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 570 | GR 6 | 51.90 |
| Skin Diseases and Diabetes | 2021-2025 | 760 | GR 1 | 35.93 |
